Luiz Magno
Luiz Magno is a senior medical director at Eli Lilly Brazil, where he has been instrumental in the development and promotion of innovative treatments for diabetes and obesity, including the recent studies highlighting the effectiveness of tirzepatida (Mounjaro) over semaglutida (Wegovy) in weight loss.
Global Media Ratings
Countries Mentioned
No country-level mention data available.
Interactive World Map
Each country's color is based on "Mentions" from the table above.
Recent Mentions
Brazil:
Luiz Magno is the senior medical director of Eli Lilly in Brazil.
8
Liechtenstein:
Luiz Magno is the senior medical director at Eli Lilly do Brasil and explains the role of GIP in weight loss results.
8